GuidelinesOther guideline
Various
Deferasirox Folinic acid, intravenous Lanthanum carbonate, Sevelamer Mesna ATC Code V03AC03 Medicine Deferasirox ( film-coated and dispersible tablets considered equivalent ) Indication Treatment of transfusional iron overload NEMLC Recommendation Approved Added as an oral alternative to deferoxamine Review Indicators n/a Date Ratified 30 November 2023 Film-coated tablet update ( Previousl
Lanthanum carbonate, Sevelamer
| ATC Code | V03AC03 |
| Medicine | Deferasirox (film-coated and dispersible tablets considered equivalent) |
| Indication | Treatment of transfusional iron overload |
| NEMLC Recommendation | Approved Added as an oral alternative to deferoxamine |
| Review Indicators | n/a |
| Date Ratified | 30 November 2023 Film-coated tablet update (Previously reviewed 15 September 2016) |
| ATC Code | V03AF03 |
| Medicine | Calcium folinate, intravenous |
| Indication | Adjuvant colorectal cancer |
| NEMLC Recommendation | Approved |
| Review Indicators | n/a |
| Date Ratified | 27 November 2008 |
| ATC Code | V03AE |
| Medicine | Lanthanum carbonate, Sevelamer |
| Indication | Hyperphosphataemia in patients with chronic renal failure |
| NEMLC Recommendation | Approved – Special Access Special Access may be granted on recommendation by the PTC |
| Review Indicators | - Evidence that the use of non-calcium-based phosphate binders significantly reduces all-cause or cardiovascular mortality and/or cardiovascular comorbidities in patients with ESRD - Reduction in cost of sevelamer through price reduction or the introduction of generic equivalents |
| Date Ratified | 25 June 2015 |
| ATC Code | V03AF01 |
| Medicine | Mesna |
| Indication | Haemorrhagic cystitis post high dose cyclophosphamide/ ifosfamide |
| NEMLC Recommendation | Approved |
| Review Indicators | n/a |
| Date Ratified | 11 July 2019 |
National Essential Medicines List Committee (NEMLC)
Tertiary and Quaternary Level Essential Medicines List
November 2023